Physician profile
Loel Fishman
NPI 1164421475
$1,527.03
in general payments reported to CMS, 2019-2025
22 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $57.44 · 2021: $101 · 2022: $405 · 2023: $237 · 2024: $201 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.97 | 2019-2025 | |
| Exact Sciences Corporation | $228.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gynesonics, INC. | $176.38 | 2022 | |
| Therapeuticsmd, INC. | $102.79 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.78 | 2020-2023 | |
| Astellas Pharma US INC | $89.58 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $89.24 | 2019-2025 | Thinprep 2000 Processor, Aptima |
| Dilon Technologies, INC. | $66.58 | 2025 | Hemoblast Bellows |
| Coopersurgical, INC. | $64.49 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Mallinckrodt Enterprises LLC | $64.07 | 2019 | |
| Myovant Sciences INC. | $41.34 | 2022 | |
| Mayne Pharma Commercial LLC | $32.84 | 2022-2023 | |
| Heron Therapeutics, INC. | $26.23 | 2023 | Zynrelef |
| Vertex Pharmaceuticals Incorporated | $24.57 | 2025 | |
| Ethicon US, LLC | $19.23 | 2025 | Stratafix, Vistaseal, Ethicon |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $17.82 | 2021 | |
| Sumitomo Pharma America, INC. | $16.92 | 2024 | Myfembree |
| Evofem Biosciences, INC. | $16.51 | 2025 | Phexxi, Solosec, Phexx |
| Uroviu Corporation | $15.27 | 2023 | Uro-G Flexible Cystoscope |
| Novo Nordisk INC | $14.36 | 2022 | |
| Smith+Nephew, INC. | $14.05 | 2025 | Pico 14 |
| Aspira Women'S Health INC | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loel Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.